The global polyclonal antibody market is poised for significant expansion in the coming decade, driven by increasing ...
AL002 misses Phase 2 goal in early Alzheimer's. Key Phase 3 data for latozinemab in 2025. Click here to read why ALEC is a ...
Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback